Bausch Health Companies Inc. BHC Financial Statement Data


2025 Q2

Submissions

Field Row 1
adsh 0000885590-25-000020
cik 885590
name BAUSCH HEALTH COMPANIES INC.
sic 2834
countryba CA
stprba QC
cityba QUEBEC
zipba H7L 4A8
bas1 2150 ST. ELZEAR BLVD. WEST
bas2 LAVAL
baph 514-744-6792
countryma CA
stprma QC
cityma QUEBEC
zipma H7L 4A8
mas1 2150 ST. ELZEAR BLVD. WEST
mas2 LAVAL
countryinc US
stprinc NJ
ein 000000000
former VALEANT PHARMACEUTICALS INTERNATIONAL, INC.
changed 20100928
afs 1-LAF
wksi 0
fye 1231
form 10-Q
period 20250331
fy 2025
fp Q1
filed 20250501
accepted 2025-04-30 18:04:00.0
prevrpt 0
detail 1
instance bhc-20250331_htm.xml
nciks 1
aciks

Description
Field Name Field Description
adsh Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission.
cik Central Index Key (CIK). Ten digit number assigned by the SEC to each registrant that submits filings.
name Name of registrant. This corresponds to the name of the legal entity as recorded in EDGAR as of the filing date.
sic Standard Industrial Classification (SIC). Four digit code assigned by the SEC as of the filing date, indicating the registrant’s type of business.
countryba The ISO 3166-1 country of the registrant's business address.
stprba The state or province of the registrant’s business address, if field countryba is US or CA.
cityba The city of the registrant's business address.
zipba The zip code of the registrant’s business address.
bas1 The first line of the street of the registrant’s business address.
bas2 The second line of the street of the registrant’s business address.
baph The phone number of the registrant’s business address.
countryma The ISO 3166-1 country of the registrant's mailing address.
stprma The state or province of the registrant’s mailing address, if field countryma is US or CA.
cityma The city of the registrant's mailing address.
zipma The zip code of the registrant’s mailing address.
mas1 The first line of the street of the registrant’s mailing address.
mas2 The second line of the street of the registrant’s mailing address.
countryinc The ISO 3166-1 country of incorporation for the registrant.
stprinc The state or province of incorporation for the registrant, if countryinc is US or CA.
ein Employee Identification Number, 9 digit identification number assigned by the Internal Revenue Service to business entities operating in the United States.
former Most recent former name of the registrant, if any.
changed Date of change from the former name, if any.
afs Filer status with the SEC at the time of submission:
1-LAF=Large Accelerated, 2-ACC=Accelerated, 3-SRA=Smaller Reporting Accelerated, 4-NON=Non-Accelerated, 5-SML=Smaller Reporting Filer, NULL=not assigned.
wksi Well Known Seasoned Issuer (WKSI). An issuer that meets specific SEC requirements at some point during a 60-day period preceding the date the issuer satisfies its obligation to update its shelf registration statement.
fye Fiscal Year End Date, rounded to nearest month-end.
form The submission type of the registrant’s filing.
period Balance Sheet Date, rounded to nearest month-end.
fy Fiscal Year Focus (as defined in the EDGAR XBRL Guide Ch. 3.1.8).
fp Fiscal Period Focus (as defined in the EDGAR XBRL Guide Ch. 3.1.8) within Fiscal Year.
filed The date of the registrant’s filing with the Commission.
accepted The acceptance date and time of the registrant’s filing with the Commission.
prevrpt Previous Report – TRUE indicates that the submission information was subsequently amended.
detail TRUE indicates that the XBRL submission contains quantitative disclosures within the footnotes and schedules at the required detail level (e.g., each amount).
instance The name of the submitted XBRL Instance Document. The name often begins with the company ticker symbol.
nciks Number of Central Index Keys (CIK) of registrants (i.e., business units) included in the consolidating entity’s submitted filing.
aciks Additional CIKs of co-registrants included in a consolidating entity’s EDGAR submission, separated by spaces. If there are no other co-registrants (i.e., nciks=1), the value of aciks is NULL. For a very small number of filers, the entire list of co-registrants is too long to fit in the field. Where this is the case, users should refer to the complete submission file for all CIK information.

Numbers

adsh ddate tag value uom qtrs version segments coreg footnote
0000885590-25-000020 20241231 Common Stock Shares Outstanding 367843058.0000 shares 0 us-gaap/2024
0000885590-25-000020 20241231 Additional Paid In Capital Common Stock 234000000.0000 USD 0 us-gaap/2024
0000885590-25-000020 20240331 Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value 33000000.0000 USD 1 us-gaap/2024 Equity Components= Additional Paid In Capital;
0000885590-25-000020 20250331 Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value 43000000.0000 USD 1 us-gaap/2024 Equity Components= Parent;
0000885590-25-000020 20241231 Assets 26523000000.0000 USD 0 us-gaap/2024
0000885590-25-000020 20241231 Assets Current 5774000000.0000 USD 0 us-gaap/2024
0000885590-25-000020 20250331 Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Asset Cash -11000000.0000 USD 1 0000885590-25-000020
0000885590-25-000020 20240331 Cost Of Goods And Services Sold 19000000.0000 USD 1 us-gaap/2024 Business Segments= Solta Medical Segment; Consolidation Items= Operating Segments; Product Or Service= Product;
0000885590-25-000020 20250331 Cost Of Goods And Services Sold 0.0000 USD 1 us-gaap/2024 Business Segments= Diversified Segment; Consolidation Items= Operating Segments; Product Or Service= Product And Service Other;
0000885590-25-000020 20250331 Cost Of Goods And Services Sold 0.0000 USD 1 us-gaap/2024 Business Segments= Solta Medical Segment; Consolidation Items= Operating Segments; Product Or Service= Product And Service Other;
0000885590-25-000020 20250331 Deferred Income Tax Assets Net 1977000000.0000 USD 0 us-gaap/2024
0000885590-25-000020 20240331 Deferred Income Tax Noncash Expense Benefit -57000000.0000 USD 1 0000885590-25-000020
0000885590-25-000020 20250331 Deferred Income Tax Noncash Expense Benefit -9000000.0000 USD 1 0000885590-25-000020
0000885590-25-000020 20250331 Accrued Liabilities Current 3354000000.0000 USD 0 us-gaap/2024
0000885590-25-000020 20250331 Accumulated Other Comprehensive Income Loss Net Of Tax -2029000000.0000 USD 0 us-gaap/2024
0000885590-25-000020 20250331 Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value 43000000.0000 USD 1 us-gaap/2024
0000885590-25-000020 20250331 Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value 43000000.0000 USD 1 us-gaap/2024 Equity Components= Additional Paid In Capital;
0000885590-25-000020 20240331 Allowances For Losses On Accounts Receivable And Inventories 15000000.0000 USD 1 0000885590-25-000020
0000885590-25-000020 20250331 Allowances For Losses On Accounts Receivable And Inventories 26000000.0000 USD 1 0000885590-25-000020
0000885590-25-000020 20250331 Amortization Of Financing Costs And Discounts 15000000.0000 USD 1 us-gaap/2024
0000885590-25-000020 20250331 Amortization Of Intangible Assets Excluding Amortization Allocated To Revenues Cost Of Good Sold 256000000.0000 USD 1 0000885590-25-000020
0000885590-25-000020 20250331 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 1157000000.0000 USD 0 us-gaap/2024
0000885590-25-000020 20240331 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect -207000000.0000 USD 1 us-gaap/2024
0000885590-25-000020 20240331 Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest -11000000.0000 USD 1 us-gaap/2024
0000885590-25-000020 20240331 Cost Of Goods And Services Sold 1000000.0000 USD 1 us-gaap/2024 Business Segments= Bausch Lomb; Consolidation Items= Operating Segments; Product Or Service= Product And Service Other;
0000885590-25-000020 20240331 Cost Of Goods And Services Sold 109000000.0000 USD 1 us-gaap/2024 Business Segments= International Rx; Consolidation Items= Operating Segments; Product Or Service= Product;
0000885590-25-000020 20240331 Cost Of Goods And Services Sold 11000000.0000 USD 1 us-gaap/2024 Business Segments= International Rx; Consolidation Items= Operating Segments; Product Or Service= Product And Service Other;
0000885590-25-000020 20240331 Cost Of Goods And Services Sold 41000000.0000 USD 1 us-gaap/2024 Business Segments= Salix Segment; Consolidation Items= Operating Segments; Product Or Service= Product;
0000885590-25-000020 20250331 Cost Of Goods And Services Sold 27000000.0000 USD 1 us-gaap/2024 Business Segments= Solta Medical Segment; Consolidation Items= Operating Segments; Product Or Service= Product;
0000885590-25-000020 20231231 Goodwill 1733000000.0000 USD 0 us-gaap/2024 Business Segments= Diversified Segment;
0000885590-25-000020 20250331 Goodwill 1744000000.0000 USD 0 us-gaap/2024 Business Segments= Diversified Segment;
0000885590-25-000020 20250331 Goodwill 829000000.0000 USD 0 us-gaap/2024 Business Segments= International Rx;
0000885590-25-000020 20241231 Intangible Assets Net Excluding Goodwill 5551000000.0000 USD 0 us-gaap/2024
0000885590-25-000020 20241231 Inventory Net 1595000000.0000 USD 0 us-gaap/2024
0000885590-25-000020 20250331 Long Term Debt Current 282000000.0000 USD 0 us-gaap/2024
0000885590-25-000020 20241231 Minority Interest 957000000.0000 USD 0 us-gaap/2024
0000885590-25-000020 20240331 Net Income Loss Attributable To Noncontrolling Interest -13000000.0000 USD 1 us-gaap/2024
0000885590-25-000020 20240331 Other Comprehensive Income Loss Net Of Tax -34000000.0000 USD 1 us-gaap/2024
0000885590-25-000020 20250331 Payment For Contingent Consideration Liability Financing Activities 7000000.0000 USD 1 us-gaap/2024
0000885590-25-000020 20240331 Payment For Contingent Consideration Liability Including Accretion Operating Activities 2000000.0000 USD 1 0000885590-25-000020
0000885590-25-000020 20250331 Payments To Acquire Intangible Assets 9000000.0000 USD 1 us-gaap/2024
0000885590-25-000020 20250331 Profit Loss -28000000.0000 USD 1 us-gaap/2024 Equity Components= Noncontrolling Interest;
0000885590-25-000020 20240331 Research And Development Expense Excluding Acquired In Process Cost 4000000.0000 USD 1 us-gaap/2024 Business Segments= Diversified Segment; Consolidation Items= Operating Segments;
0000885590-25-000020 20250331 Research And Development Expense Excluding Acquired In Process Cost 17000000.0000 USD 1 us-gaap/2024 Business Segments= Salix Segment; Consolidation Items= Operating Segments;
0000885590-25-000020 20241231 Restricted Cash Current 20000000.0000 USD 0 us-gaap/2024 Fair Value By Fair Value Hierarchy Level= Fair Value Inputs Level1; Fair Value By Measurement Frequency= Fair Value Measurements Recurring;
0000885590-25-000020 20240331 Revenue From Contract With Customer Excluding Assessed Tax 1099000000.0000 USD 1 us-gaap/2024 Business Segments= Bausch Lomb; Consolidation Items= Operating Segments;
0000885590-25-000020 20250331 Revenue From Contract With Customer Excluding Assessed Tax 2227000000.0000 USD 1 us-gaap/2024 Product Or Service= Product;
0000885590-25-000020 20250331 Selling General And Administrative Expense 52000000.0000 USD 1 us-gaap/2024 Business Segments= International Rx; Consolidation Items= Operating Segments;
0000885590-25-000020 20250331 Selling General And Administrative Expense 111000000.0000 USD 1 us-gaap/2024 Business Segments= Salix Segment; Consolidation Items= Operating Segments;
0000885590-25-000020 20231231 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 940000000.0000 USD 0 us-gaap/2024 Equity Components= Noncontrolling Interest;
0000885590-25-000020 20231231 Stockholders Equity Including Portion Attributable To Noncontrolling Interest -9778000000.0000 USD 0 us-gaap/2024 Equity Components= Retained Earnings;
0000885590-25-000020 20250331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 10508000000.0000 USD 0 us-gaap/2024 Equity Components= Common Stock;
0000885590-25-000020 20240331 Stock Issued During Period Value Share Based Compensation -57000000.0000 USD 1 us-gaap/2024 Equity Components= Additional Paid In Capital;
0000885590-25-000020 20250331 Stock Issued During Period Value Share Based Compensation 18000000.0000 USD 1 us-gaap/2024 Equity Components= Common Stock;
0000885590-25-000020 20240331 Amortization Interim Contract And Inventory Step From Acquisition 20000000.0000 USD 1 0000885590-25-000020
0000885590-25-000020 20250331 Assets 26421000000.0000 USD 0 us-gaap/2024
0000885590-25-000020 20250331 Cash And Cash Equivalents At Carrying Value 1134000000.0000 USD 0 us-gaap/2024
0000885590-25-000020 20250331 Cash And Cash Equivalents At Carrying Value 215000000.0000 USD 0 us-gaap/2024 Legal Entity= Bausch Lomb; BauschLomb
0000885590-25-000020 20240331 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 755000000.0000 USD 0 us-gaap/2024
0000885590-25-000020 20250331 Commitments And Contingencies USD 0 us-gaap/2024
0000885590-25-000020 20250331 Common Stock Value 10508000000.0000 USD 0 us-gaap/2024
0000885590-25-000020 20250331 Cost Of Goods And Services Sold 30000000.0000 USD 1 us-gaap/2024 Business Segments= Diversified Segment; Consolidation Items= Operating Segments; Product Or Service= Product;
0000885590-25-000020 20250331 Earnings Per Share Basic -0.1600 USD 1 us-gaap/2024
0000885590-25-000020 20240331 Foreign Currency Transaction And Other Gain Loss Before Tax 4000000.0000 USD 1 0000885590-25-000020
0000885590-25-000020 20240331 Foreign Currency Transaction Gain Loss Before Tax -15000000.0000 USD 1 us-gaap/2024
0000885590-25-000020 20231231 Goodwill 862000000.0000 USD 0 us-gaap/2024 Business Segments= International Rx;
0000885590-25-000020 20231231 Goodwill 115000000.0000 USD 0 us-gaap/2024 Business Segments= Solta Medical Segment;
0000885590-25-000020 20240331 Increase Decrease In Accounts Receivable 63000000.0000 USD 1 us-gaap/2024
0000885590-25-000020 20250331 Increase Decrease In Prepaid Deferred Expense And Other Assets 46000000.0000 USD 1 us-gaap/2024
0000885590-25-000020 20240331 Interest Expense Debt 355000000.0000 USD 1 us-gaap/2024
0000885590-25-000020 20250331 Interest Expense Debt 330000000.0000 USD 1 us-gaap/2024
0000885590-25-000020 20250331 Long Term Debt Noncurrent 21228000000.0000 USD 0 us-gaap/2024
0000885590-25-000020 20250331 Minority Interest 943000000.0000 USD 0 us-gaap/2024
0000885590-25-000020 20250331 Net Income Loss -58000000.0000 USD 1 us-gaap/2024
0000885590-25-000020 20250331 Noncontrolling Interest Increase From Subsidiary Equity Issuance 0.0000 USD 1 us-gaap/2024
0000885590-25-000020 20250331 Operating Income Loss 276000000.0000 USD 1 us-gaap/2024
0000885590-25-000020 20250331 Operating Income Loss 127000000.0000 USD 1 us-gaap/2024 Business Segments= Diversified Segment; Consolidation Items= Operating Segments;
0000885590-25-000020 20250331 Other Comprehensive Income Loss Net Of Tax 150000000.0000 USD 1 us-gaap/2024 Equity Components= Parent;
0000885590-25-000020 20240331 Other Operating Income Expense Net 0.0000 USD 1 us-gaap/2024
0000885590-25-000020 20240331 Payment For Contingent Consideration Liability Financing Activities 7000000.0000 USD 1 us-gaap/2024
0000885590-25-000020 20250331 Payment For Contingent Consideration Liability Including Accretion Operating Activities 2000000.0000 USD 1 0000885590-25-000020
0000885590-25-000020 20250331 Payments To Acquire Businesses And For Other Investments 12000000.0000 USD 1 0000885590-25-000020
0000885590-25-000020 20250331 Payments To Acquire Marketable Securities 4000000.0000 USD 1 us-gaap/2024
0000885590-25-000020 20240331 Proceeds From Divestiture Of Businesses Net Of Cash Divested 1000000.0000 USD 1 us-gaap/2024
0000885590-25-000020 20250331 Proceeds From Divestiture Of Businesses Net Of Cash Divested 0.0000 USD 1 us-gaap/2024
0000885590-25-000020 20250331 Proceeds From Sale And Maturity Of Marketable Securities 4000000.0000 USD 1 us-gaap/2024
0000885590-25-000020 20240331 Profit Loss -13000000.0000 USD 1 us-gaap/2024 Equity Components= Noncontrolling Interest;
0000885590-25-000020 20240331 Profit Loss -64000000.0000 USD 1 us-gaap/2024 Equity Components= Parent;
0000885590-25-000020 20241231 Receivables Net Current 2140000000.0000 USD 0 us-gaap/2024
0000885590-25-000020 20240331 Research And Development Expense Excluding Acquired In Process Cost 4000000.0000 USD 1 us-gaap/2024 Business Segments= Solta Medical Segment; Consolidation Items= Operating Segments;
0000885590-25-000020 20250331 Research And Development Expense Excluding Acquired In Process Cost 143000000.0000 USD 1 us-gaap/2024
0000885590-25-000020 20250331 Research And Development Expense Excluding Acquired In Process Cost 5000000.0000 USD 1 us-gaap/2024 Business Segments= Solta Medical Segment; Consolidation Items= Operating Segments;
0000885590-25-000020 20250331 Restricted Cash Current 23000000.0000 USD 0 us-gaap/2024 Fair Value By Fair Value Hierarchy Level= Fair Value Inputs Level1; Fair Value By Measurement Frequency= Fair Value Measurements Recurring;
0000885590-25-000020 20240331 Restructuring Charges And Initial Public Offering Costs 12000000.0000 USD 1 0000885590-25-000020
0000885590-25-000020 20240331 Revenue From Contract With Customer Excluding Assessed Tax 265000000.0000 USD 1 us-gaap/2024 Business Segments= International Rx; Consolidation Items= Operating Segments;
0000885590-25-000020 20240331 Revenue From Contract With Customer Excluding Assessed Tax 2129000000.0000 USD 1 us-gaap/2024 Product Or Service= Product;
0000885590-25-000020 20250331 Revenue From Contract With Customer Excluding Assessed Tax 205000000.0000 USD 1 us-gaap/2024 Business Segments= Diversified Segment; Consolidation Items= Operating Segments;
0000885590-25-000020 20250331 Revenue From Contract With Customer Excluding Assessed Tax 542000000.0000 USD 1 us-gaap/2024 Business Segments= Salix Segment; Consolidation Items= Operating Segments;
0000885590-25-000020 20250331 Revenue From Contract With Customer Excluding Assessed Tax 113000000.0000 USD 1 us-gaap/2024 Business Segments= Solta Medical Segment; Consolidation Items= Operating Segments;
0000885590-25-000020 20250331 Revenue From Contract With Customer Excluding Assessed Tax 32000000.0000 USD 1 us-gaap/2024 Product Or Service= Product And Service Other;
0000885590-25-000020 20240331 Selling General And Administrative Expense 53000000.0000 USD 1 us-gaap/2024 Business Segments= International Rx; Consolidation Items= Operating Segments;
0000885590-25-000020 20231231 Stockholders Equity Including Portion Attributable To Noncontrolling Interest -82000000.0000 USD 0 us-gaap/2024
0000885590-25-000020 20231231 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 10423000000.0000 USD 0 us-gaap/2024 Equity Components= Common Stock;
0000885590-25-000020 20240331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest -1917000000.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0000885590-25-000020 20241231 Stockholders Equity Including Portion Attributable To Noncontrolling Interest -2162000000.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Translation Adjustment;
0000885590-25-000020 20241231 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 234000000.0000 USD 0 us-gaap/2024 Equity Components= Additional Paid In Capital;
0000885590-25-000020 20250331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest -240000000.0000 USD 0 us-gaap/2024
0000885590-25-000020 20250331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 220000000.0000 USD 0 us-gaap/2024 Equity Components= Additional Paid In Capital;
0000885590-25-000020 20250331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest -1183000000.0000 USD 0 us-gaap/2024 Equity Components= Parent;
0000885590-25-000020 20250331 Stock Issued During Period Shares Share Based Compensation 1700000.0000 shares 1 us-gaap/2024 Equity Components= Common Stock;
0000885590-25-000020 20240331 Stock Issued During Period Value Share Based Compensation 0.0000 USD 1 us-gaap/2024
0000885590-25-000020 20240331 Weighted Average Number Of Diluted Shares Outstanding 366800000.0000 shares 1 us-gaap/2024
0000885590-25-000020 20241231 Accrued Liabilities Current 3489000000.0000 USD 0 us-gaap/2024
0000885590-25-000020 20250331 Additional Paid In Capital Common Stock 220000000.0000 USD 0 us-gaap/2024
0000885590-25-000020 20250331 Adjustments Related To Tax Withholding For Share Based Compensation 16000000.0000 USD 1 us-gaap/2024
0000885590-25-000020 20250331 Adjustments Related To Tax Withholding For Share Based Compensation 16000000.0000 USD 1 us-gaap/2024 Equity Components= Additional Paid In Capital;
0000885590-25-000020 20240331 Asset Impairment Charges 1000000.0000 USD 1 us-gaap/2024
0000885590-25-000020 20250331 Assets Current 5732000000.0000 USD 0 us-gaap/2024
0000885590-25-000020 20250331 Common Stock Shares Outstanding 369539455.0000 shares 0 us-gaap/2024
0000885590-25-000020 20250331 Common Stock Shares Outstanding 185468421.0000 shares 0 us-gaap/2024 Ownership= Bausch Lomb; Subsequent Event Type= Subsequent Event;
0000885590-25-000020 20250331 Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest 55000000.0000 USD 1 us-gaap/2024
0000885590-25-000020 20250331 Cost Of Goods And Services Sold 17000000.0000 USD 1 us-gaap/2024 Business Segments= International Rx; Consolidation Items= Operating Segments; Product Or Service= Product And Service Other;
0000885590-25-000020 20241231 Deferred Income Tax Assets Net 1968000000.0000 USD 0 us-gaap/2024
0000885590-25-000020 20250331 Depreciation And Amortization 305000000.0000 USD 1 us-gaap/2024
0000885590-25-000020 20250331 Earnings Per Share Diluted -0.1600 USD 1 us-gaap/2024
0000885590-25-000020 20240331 Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents -5000000.0000 USD 1 us-gaap/2024
0000885590-25-000020 20250331 Foreign Currency Transaction And Other Gain Loss Before Tax 2000000.0000 USD 1 0000885590-25-000020
0000885590-25-000020 20241231 Goodwill 1759000000.0000 USD 0 us-gaap/2024 Business Segments= Diversified Segment;
0000885590-25-000020 20241231 Goodwill 3159000000.0000 USD 0 us-gaap/2024 Business Segments= Salix Segment;
0000885590-25-000020 20240331 Income Tax Expense Benefit 8000000.0000 USD 1 us-gaap/2024
0000885590-25-000020 20250331 Income Tax Expense Benefit 39000000.0000 USD 1 us-gaap/2024
0000885590-25-000020 20250331 Inventory Net 1613000000.0000 USD 0 us-gaap/2024
0000885590-25-000020 20241231 Liabilities And Stockholders Equity 26523000000.0000 USD 0 us-gaap/2024
0000885590-25-000020 20240331 Noncontrolling Interest Increase From Subsidiary Equity Issuance -12000000.0000 USD 1 us-gaap/2024 Equity Components= Additional Paid In Capital;
0000885590-25-000020 20240331 Operating Income Loss 281000000.0000 USD 1 us-gaap/2024
0000885590-25-000020 20240331 Operating Income Loss 87000000.0000 USD 1 us-gaap/2024 Business Segments= International Rx; Consolidation Items= Operating Segments;
0000885590-25-000020 20240331 Operating Income Loss 329000000.0000 USD 1 us-gaap/2024 Business Segments= Salix Segment; Consolidation Items= Operating Segments;
0000885590-25-000020 20240331 Payments Related To Tax Withholding For Share Based Compensation 14000000.0000 USD 1 us-gaap/2024
0000885590-25-000020 20240331 Payments To Acquire Marketable Securities 3000000.0000 USD 1 us-gaap/2024
0000885590-25-000020 20240331 Proceeds From Sale And Maturity Of Marketable Securities 6000000.0000 USD 1 us-gaap/2024
0000885590-25-000020 20240531 Repayments Of Long Term Debt 530000000.0000 USD 2 us-gaap/2024 Longterm Debt Type= Unsecured Debt;
0000885590-25-000020 20250331 Revenue From Contract With Customer Excluding Assessed Tax 262000000.0000 USD 1 us-gaap/2024 Business Segments= International Rx; Consolidation Items= Operating Segments;
0000885590-25-000020 20250331 Revenue From Contract With Customer Excluding Assessed Tax 2000000.0000 USD 1 us-gaap/2024 Product Or Service= Price Appreciation Credit;
0000885590-25-000020 20240331 Selling General And Administrative Expense 102000000.0000 USD 1 us-gaap/2024 Business Segments= Salix Segment; Consolidation Items= Operating Segments;
0000885590-25-000020 20250331 Selling General And Administrative Expense 45000000.0000 USD 1 us-gaap/2024 Business Segments= Diversified Segment; Consolidation Items= Operating Segments;
0000885590-25-000020 20250331 Selling General And Administrative Expense 5000000.0000 USD 1 us-gaap/2024 Restructuring Cost And Reserve= Separation And Initial Public Offering Costs;
0000885590-25-000020 20240331 Share Based Compensation 33000000.0000 USD 1 us-gaap/2024
0000885590-25-000020 20241231 Stockholders Equity -1279000000.0000 USD 0 us-gaap/2024
0000885590-25-000020 20240331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 10480000000.0000 USD 0 us-gaap/2024 Equity Components= Common Stock;
0000885590-25-000020 20250331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest -17000000.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Defined Benefit Plans Adjustment;
0000885590-25-000020 20250331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest -2012000000.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Translation Adjustment;
0000885590-25-000020 20250331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 943000000.0000 USD 0 us-gaap/2024 Equity Components= Noncontrolling Interest;
0000885590-25-000020 20250331 Weighted Average Number Of Shares Outstanding Basic 369600000.0000 shares 1 us-gaap/2024
0000885590-25-000020 20240331 Payments For Proceeds From Hedge Investing Activities -6000000.0000 USD 1 us-gaap/2024
0000885590-25-000020 20241231 Prepaid Expense And Other Assets Current 838000000.0000 USD 0 us-gaap/2024
0000885590-25-000020 20241231 Accumulated Other Comprehensive Income Loss Net Of Tax -2179000000.0000 USD 0 us-gaap/2024
0000885590-25-000020 20250331 Amortization Interim Contract And Inventory Step From Acquisition 22000000.0000 USD 1 0000885590-25-000020
0000885590-25-000020 20250331 Asset Impairment Charges 0.0000 USD 1 us-gaap/2024
0000885590-25-000020 20240331 Cash And Cash Equivalents At Carrying Value 733000000.0000 USD 0 us-gaap/2024
0000885590-25-000020 20241231 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 1201000000.0000 USD 0 us-gaap/2024
0000885590-25-000020 20250331 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect -44000000.0000 USD 1 us-gaap/2024
0000885590-25-000020 20240331 Common Stock Shares Issued 366700000.0000 shares 0 us-gaap/2024 Equity Components= Common Stock;
0000885590-25-000020 20241231 Common Stock Shares Issued 367800000.0000 shares 0 us-gaap/2024 Equity Components= Common Stock;
0000885590-25-000020 20250331 Cost Of Goods And Services Sold 1000000.0000 USD 1 us-gaap/2024 Business Segments= Bausch Lomb; Consolidation Items= Operating Segments; Product Or Service= Product And Service Other;
0000885590-25-000020 20250331 Cost Of Goods And Services Sold 0.0000 USD 1 us-gaap/2024 Business Segments= Salix Segment; Consolidation Items= Operating Segments; Product Or Service= Product And Service Other;
0000885590-25-000020 20250331 Cost Of Goods And Services Sold 18000000.0000 USD 1 us-gaap/2024 Product Or Service= Product And Service Other;
0000885590-25-000020 20240331 Costs And Expenses 1872000000.0000 USD 1 us-gaap/2024
0000885590-25-000020 20250331 Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 21000000.0000 USD 1 us-gaap/2024
0000885590-25-000020 20240331 Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value 33000000.0000 USD 1 us-gaap/2024
0000885590-25-000020 20220531 Common Stock Shares Outstanding 310449643.0000 shares 0 us-gaap/2024 Ownership= Bausch Lomb;
0000885590-25-000020 20250331 Common Stock Shares Outstanding 185468421.0000 shares 0 us-gaap/2024 Debt Instrument= A2025 Credit Agreement; Ownership= Bausch Lomb; Pledged Status= Asset Pledged As Collateral;
0000885590-25-000020 20240331 Comprehensive Income Net Of Tax -100000000.0000 USD 1 us-gaap/2024
0000885590-25-000020 20240331 Cost Of Goods And Services Sold 12000000.0000 USD 1 us-gaap/2024 Product Or Service= Product And Service Other;
0000885590-25-000020 20250331 Gain Loss Related To Litigation Settlement Gross 3000000.0000 USD 1 0000885590-25-000020
0000885590-25-000020 20250331 Cost Of Goods And Services Sold 102000000.0000 USD 1 us-gaap/2024 Business Segments= International Rx; Consolidation Items= Operating Segments; Product Or Service= Product;
0000885590-25-000020 20250331 Cost Of Goods And Services Sold 43000000.0000 USD 1 us-gaap/2024 Business Segments= Salix Segment; Consolidation Items= Operating Segments; Product Or Service= Product;
0000885590-25-000020 20240531 Gains Losses On Extinguishment Of Debt 23000000.0000 USD 2 us-gaap/2024 Longterm Debt Type= Unsecured Debt;
0000885590-25-000020 20241231 Goodwill 5262000000.0000 USD 0 us-gaap/2024 Business Segments= Bausch Lomb;
0000885590-25-000020 20250331 Goodwill 115000000.0000 USD 0 us-gaap/2024 Business Segments= Solta Medical Segment;
0000885590-25-000020 20250331 Increase Decrease In Accounts Payable And Accrued Liabilities -99000000.0000 USD 1 us-gaap/2024
0000885590-25-000020 20240331 Increase Decrease In Inventories 144000000.0000 USD 1 us-gaap/2024
0000885590-25-000020 20250331 Increase Decrease In Inventories 30000000.0000 USD 1 us-gaap/2024
0000885590-25-000020 20250331 Gains Losses On Extinguishment Of Debt 0.0000 USD 1 us-gaap/2024
0000885590-25-000020 20241231 Goodwill 11087000000.0000 USD 0 us-gaap/2024
0000885590-25-000020 20241231 Goodwill 792000000.0000 USD 0 us-gaap/2024 Business Segments= International Rx;
0000885590-25-000020 20241231 Goodwill 115000000.0000 USD 0 us-gaap/2024 Business Segments= Solta Medical Segment;
0000885590-25-000020 20250331 Investment Income Interest 11000000.0000 USD 1 us-gaap/2024
0000885590-25-000020 20250331 Net Income Loss Attributable To Noncontrolling Interest -28000000.0000 USD 1 us-gaap/2024
0000885590-25-000020 20240331 Noncontrolling Interest Increase From Subsidiary Equity Issuance -12000000.0000 USD 1 us-gaap/2024 Equity Components= Parent;
0000885590-25-000020 20240331 Operating Income Loss 40000000.0000 USD 1 us-gaap/2024 Business Segments= Solta Medical Segment; Consolidation Items= Operating Segments;
0000885590-25-000020 20240331 Increase Decrease In Prepaid Deferred Expense And Other Assets -121000000.0000 USD 1 us-gaap/2024
0000885590-25-000020 20241231 Long Term Debt Noncurrent 18942000000.0000 USD 0 us-gaap/2024
0000885590-25-000020 20250331 Net Cash Provided By Used In Investing Activities -130000000.0000 USD 1 us-gaap/2024
0000885590-25-000020 20250331 Noncontrolling Interest Increase From Subsidiary Equity Issuance -23000000.0000 USD 1 us-gaap/2024 Equity Components= Additional Paid In Capital;
0000885590-25-000020 20240331 Operating Income Loss 114000000.0000 USD 1 us-gaap/2024 Business Segments= Diversified Segment; Consolidation Items= Operating Segments;
0000885590-25-000020 20250331 Operating Income Loss 85000000.0000 USD 1 us-gaap/2024 Business Segments= International Rx; Consolidation Items= Operating Segments;
0000885590-25-000020 20240331 Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax -34000000.0000 USD 1 us-gaap/2024
0000885590-25-000020 20250331 Other Comprehensive Income Loss Net Of Tax 141000000.0000 USD 1 us-gaap/2024
0000885590-25-000020 20241231 Restricted Cash Current 0.0000 USD 0 us-gaap/2024 Fair Value By Fair Value Hierarchy Level= Fair Value Inputs Level2; Fair Value By Measurement Frequency= Fair Value Measurements Recurring;
0000885590-25-000020 20241231 Restricted Cash Current 0.0000 USD 0 us-gaap/2024 Fair Value By Fair Value Hierarchy Level= Fair Value Inputs Level3; Fair Value By Measurement Frequency= Fair Value Measurements Recurring;
0000885590-25-000020 20250331 Revenue From Contract With Customer Excluding Assessed Tax 2259000000.0000 USD 1 us-gaap/2024 Consolidation Items= Operating Segments;
0000885590-25-000020 20240331 Selling General And Administrative Expense 25000000.0000 USD 1 us-gaap/2024 Business Segments= Solta Medical Segment; Consolidation Items= Operating Segments;
0000885590-25-000020 20240331 Selling General And Administrative Expense 5000000.0000 USD 1 us-gaap/2024 Restructuring Cost And Reserve= Separation And Initial Public Offering Costs;
0000885590-25-000020 20241231 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 957000000.0000 USD 0 us-gaap/2024 Equity Components= Noncontrolling Interest;
0000885590-25-000020 20241231 Stockholders Equity Including Portion Attributable To Noncontrolling Interest -9824000000.0000 USD 0 us-gaap/2024 Equity Components= Retained Earnings;
0000885590-25-000020 20250331 Operating Income Loss 53000000.0000 USD 1 us-gaap/2024 Business Segments= Solta Medical Segment; Consolidation Items= Operating Segments;
0000885590-25-000020 20250331 Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax 141000000.0000 USD 1 us-gaap/2024
0000885590-25-000020 20250331 Other Comprehensive Income Loss Net Of Tax 150000000.0000 USD 1 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0000885590-25-000020 20241231 Other Liabilities Noncurrent 713000000.0000 USD 0 us-gaap/2024
0000885590-25-000020 20250331 Payments For Legal Settlements 19000000.0000 USD 1 us-gaap/2024
0000885590-25-000020 20240331 Proceeds From Issuance Of Long Term Debt 75000000.0000 USD 1 us-gaap/2024
0000885590-25-000020 20250331 Profit Loss -58000000.0000 USD 1 us-gaap/2024 Equity Components= Parent;
0000885590-25-000020 20241231 Property Plant And Equipment Net 1780000000.0000 USD 0 us-gaap/2024
0000885590-25-000020 20250331 Property Plant And Equipment Net 1882000000.0000 USD 0 us-gaap/2024
0000885590-25-000020 20241231 Retained Earnings Accumulated Deficit -9824000000.0000 USD 0 us-gaap/2024
0000885590-25-000020 20240331 Revenue From Contract With Customer Excluding Assessed Tax 24000000.0000 USD 1 us-gaap/2024 Product Or Service= Product And Service Other;
0000885590-25-000020 20250331 Selling General And Administrative Expense 447000000.0000 USD 1 us-gaap/2024 Business Segments= Bausch Lomb; Consolidation Items= Operating Segments;
0000885590-25-000020 20250331 Share Based Compensation 43000000.0000 USD 1 us-gaap/2024
0000885590-25-000020 20231231 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 214000000.0000 USD 0 us-gaap/2024 Equity Components= Additional Paid In Capital;
0000885590-25-000020 20240331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest -1115000000.0000 USD 0 us-gaap/2024 Equity Components= Parent;
0000885590-25-000020 20240331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest -9842000000.0000 USD 0 us-gaap/2024 Equity Components= Retained Earnings;
0000885590-25-000020 20241231 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 10490000000.0000 USD 0 us-gaap/2024 Equity Components= Common Stock;
0000885590-25-000020 20250331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest -2029000000.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0000885590-25-000020 20240331 Stock Issued During Period Value Share Based Compensation 57000000.0000 USD 1 us-gaap/2024 Equity Components= Common Stock;
0000885590-25-000020 20250331 Stock Issued During Period Value Share Based Compensation -18000000.0000 USD 1 us-gaap/2024 Equity Components= Additional Paid In Capital;
0000885590-25-000020 20240331 Weighted Average Number Of Shares Outstanding Basic 366800000.0000 shares 1 us-gaap/2024
0000885590-25-000020 20240331 Depreciation And Amortization 320000000.0000 USD 1 us-gaap/2024
0000885590-25-000020 20241231 Accounts Payable Current 589000000.0000 USD 0 us-gaap/2024
0000885590-25-000020 20250331 Accounts Payable Current 620000000.0000 USD 0 us-gaap/2024
0000885590-25-000020 20240331 Adjustments Related To Tax Withholding For Share Based Compensation 14000000.0000 USD 1 us-gaap/2024 Equity Components= Parent;
0000885590-25-000020 20240331 Amortization Of Financing Costs And Discounts 14000000.0000 USD 1 us-gaap/2024
0000885590-25-000020 20240331 Amortization Of Intangible Assets Excluding Amortization Allocated To Revenues Cost Of Good Sold 274000000.0000 USD 1 0000885590-25-000020
0000885590-25-000020 20240331 Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Asset Cash -2000000.0000 USD 1 0000885590-25-000020
0000885590-25-000020 20231231 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 962000000.0000 USD 0 us-gaap/2024
0000885590-25-000020 20231231 Common Stock Shares Issued 365200000.0000 shares 0 us-gaap/2024 Equity Components= Common Stock;
0000885590-25-000020 20241231 Common Stock Shares Issued 367843058.0000 shares 0 us-gaap/2024
0000885590-25-000020 20250331 Common Stock Shares Issued 369539455.0000 shares 0 us-gaap/2024
0000885590-25-000020 20250331 Common Stock Shares Issued 369500000.0000 shares 0 us-gaap/2024 Equity Components= Common Stock;
0000885590-25-000020 20250331 Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest -37000000.0000 USD 1 us-gaap/2024
0000885590-25-000020 20240331 Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest -111000000.0000 USD 1 us-gaap/2024
0000885590-25-000020 20240331 Cost Of Goods And Services Sold 0.0000 USD 1 us-gaap/2024 Business Segments= Diversified Segment; Consolidation Items= Operating Segments; Product Or Service= Product And Service Other;
0000885590-25-000020 20240331 Cost Of Goods And Services Sold 0.0000 USD 1 us-gaap/2024 Business Segments= Solta Medical Segment; Consolidation Items= Operating Segments; Product Or Service= Product And Service Other;
0000885590-25-000020 20240331 Cost Of Goods And Services Sold 628000000.0000 USD 1 us-gaap/2024 Product Or Service= Product;
0000885590-25-000020 20250331 Cost Of Goods And Services Sold 481000000.0000 USD 1 us-gaap/2024 Business Segments= Bausch Lomb; Consolidation Items= Operating Segments; Product Or Service= Product;
0000885590-25-000020 20241231 Deferred Income Tax Liabilities Net 128000000.0000 USD 0 us-gaap/2024
0000885590-25-000020 20250331 Deferred Income Tax Liabilities Net 134000000.0000 USD 0 us-gaap/2024
0000885590-25-000020 20240331 Derivative Gain Excluded Component 3000000.0000 USD 1 0000885590-25-000020
0000885590-25-000020 20240331 Earnings Per Share Basic -0.1700 USD 1 us-gaap/2024
0000885590-25-000020 20240331 Gains Losses On Extinguishment Of Debt 11000000.0000 USD 1 us-gaap/2024
0000885590-25-000020 20231231 Goodwill 3159000000.0000 USD 0 us-gaap/2024 Business Segments= Salix Segment;
0000885590-25-000020 20250331 Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest -47000000.0000 USD 1 us-gaap/2024
0000885590-25-000020 20240331 Increase Decrease In Accounts Payable And Accrued Liabilities 51000000.0000 USD 1 us-gaap/2024
0000885590-25-000020 20250331 Liabilities Current 4256000000.0000 USD 0 us-gaap/2024
0000885590-25-000020 20241231 Long Term Debt Current 2674000000.0000 USD 0 us-gaap/2024
0000885590-25-000020 20250331 Net Cash Provided By Used In Operating Activities 211000000.0000 USD 1 us-gaap/2024
0000885590-25-000020 20250331 Operating Income Loss 180000000.0000 USD 1 us-gaap/2024 Business Segments= Bausch Lomb; Consolidation Items= Operating Segments;
0000885590-25-000020 20250331 Operating Income Loss -268000000.0000 USD 1 us-gaap/2024 Consolidation Items= Corporate Non Segment;
0000885590-25-000020 20240331 Other Comprehensive Income Loss Net Of Tax -36000000.0000 USD 1 us-gaap/2024 Equity Components= Parent;
0000885590-25-000020 20250331 Payments For Proceeds From Hedge Investing Activities 6000000.0000 USD 1 us-gaap/2024 Derivative Instrument Risk= Currency Swap;
0000885590-25-000020 20240331 Payments Of Debt Issuance Costs 4000000.0000 USD 1 us-gaap/2024
0000885590-25-000020 20240331 Payments To Acquire Businesses And For Other Investments 0.0000 USD 1 0000885590-25-000020
0000885590-25-000020 20250331 Payments To Acquire Property Plant And Equipment 115000000.0000 USD 1 us-gaap/2024
0000885590-25-000020 20250331 Receivables Net Current 2072000000.0000 USD 0 us-gaap/2024
0000885590-25-000020 20240331 Repayments Of Long Term Debt 390000000.0000 USD 1 us-gaap/2024
0000885590-25-000020 20250331 Repayments Of Long Term Debt 168000000.0000 USD 1 us-gaap/2024
0000885590-25-000020 20240331 Research And Development Expense Excluding Acquired In Process Cost 151000000.0000 USD 1 us-gaap/2024
0000885590-25-000020 20240331 Research And Development Expense Excluding Acquired In Process Cost 28000000.0000 USD 1 us-gaap/2024 Business Segments= Bausch Lomb; Consolidation Items= Operating Segments;
0000885590-25-000020 20240331 Research And Development Expense Excluding Acquired In Process Cost 27000000.0000 USD 1 us-gaap/2024 Business Segments= Salix Segment; Consolidation Items= Operating Segments;
0000885590-25-000020 20250331 Research And Development Expense Excluding Acquired In Process Cost 3000000.0000 USD 1 us-gaap/2024 Business Segments= Diversified Segment; Consolidation Items= Operating Segments;
0000885590-25-000020 20240331 Restricted Cash Current 22000000.0000 USD 0 us-gaap/2024
0000885590-25-000020 20241231 Restricted Cash Current 20000000.0000 USD 0 us-gaap/2024
0000885590-25-000020 20250331 Restricted Cash Current 23000000.0000 USD 0 us-gaap/2024
0000885590-25-000020 20250331 Restricted Cash Current 0.0000 USD 0 us-gaap/2024 Fair Value By Fair Value Hierarchy Level= Fair Value Inputs Level2; Fair Value By Measurement Frequency= Fair Value Measurements Recurring;
0000885590-25-000020 20250331 Retained Earnings Accumulated Deficit -9882000000.0000 USD 0 us-gaap/2024
0000885590-25-000020 20240331 Revenue From Contract With Customer Excluding Assessed Tax 202000000.0000 USD 1 us-gaap/2024 Business Segments= Diversified Segment; Consolidation Items= Operating Segments;
0000885590-25-000020 20240331 Revenue From Contract With Customer Excluding Assessed Tax 0.0000 USD 1 us-gaap/2024 Product Or Service= Price Appreciation Credit;
0000885590-25-000020 20250331 Selling General And Administrative Expense 867000000.0000 USD 1 us-gaap/2024
0000885590-25-000020 20250331 Selling General And Administrative Expense 28000000.0000 USD 1 us-gaap/2024 Business Segments= Solta Medical Segment; Consolidation Items= Operating Segments;
0000885590-25-000020 20250331 Stockholders Equity -1183000000.0000 USD 0 us-gaap/2024
0000885590-25-000020 20240331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 941000000.0000 USD 0 us-gaap/2024 Equity Components= Noncontrolling Interest;
0000885590-25-000020 20241231 Stockholders Equity Including Portion Attributable To Noncontrolling Interest -322000000.0000 USD 0 us-gaap/2024
0000885590-25-000020 20241231 Stockholders Equity Including Portion Attributable To Noncontrolling Interest -1279000000.0000 USD 0 us-gaap/2024 Equity Components= Parent;
0000885590-25-000020 20250331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest -9882000000.0000 USD 0 us-gaap/2024 Equity Components= Retained Earnings;
0000885590-25-000020 20240331 Adjustments Related To Tax Withholding For Share Based Compensation 14000000.0000 USD 1 us-gaap/2024
0000885590-25-000020 20240331 Adjustments Related To Tax Withholding For Share Based Compensation 14000000.0000 USD 1 us-gaap/2024 Equity Components= Additional Paid In Capital;
0000885590-25-000020 20250331 Adjustments Related To Tax Withholding For Share Based Compensation 16000000.0000 USD 1 us-gaap/2024 Equity Components= Parent;
0000885590-25-000020 20240331 Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value 33000000.0000 USD 1 us-gaap/2024 Equity Components= Parent;
0000885590-25-000020 20241231 Business Combination Contingent Consideration Noncurrent Liability 310000000.0000 USD 0 0000885590-25-000020
0000885590-25-000020 20250331 Business Combination Contingent Consideration Noncurrent Liability 282000000.0000 USD 0 0000885590-25-000020
0000885590-25-000020 20241231 Cash And Cash Equivalents At Carrying Value 1181000000.0000 USD 0 us-gaap/2024
0000885590-25-000020 20241231 Commitments And Contingencies USD 0 us-gaap/2024
0000885590-25-000020 20241231 Common Stock Value 10490000000.0000 USD 0 us-gaap/2024
0000885590-25-000020 20250331 Comprehensive Income Net Of Tax 92000000.0000 USD 1 us-gaap/2024
0000885590-25-000020 20240331 Cost Of Goods And Services Sold 423000000.0000 USD 1 us-gaap/2024 Business Segments= Bausch Lomb; Consolidation Items= Operating Segments; Product Or Service= Product;
0000885590-25-000020 20240331 Cost Of Goods And Services Sold 36000000.0000 USD 1 us-gaap/2024 Business Segments= Diversified Segment; Consolidation Items= Operating Segments; Product Or Service= Product;
0000885590-25-000020 20240331 Cost Of Goods And Services Sold 0.0000 USD 1 us-gaap/2024 Business Segments= Salix Segment; Consolidation Items= Operating Segments; Product Or Service= Product And Service Other;
0000885590-25-000020 20250331 Cost Of Goods And Services Sold 683000000.0000 USD 1 us-gaap/2024 Product Or Service= Product;
0000885590-25-000020 20250331 Costs And Expenses 1983000000.0000 USD 1 us-gaap/2024
0000885590-25-000020 20240331 Earnings Per Share Diluted -0.1700 USD 1 us-gaap/2024
0000885590-25-000020 20250331 Foreign Currency Transaction Gain Loss Before Tax -4000000.0000 USD 1 us-gaap/2024
0000885590-25-000020 20240331 Gain Loss On Disposition Of Assets1 4000000.0000 USD 1 us-gaap/2024
0000885590-25-000020 20250331 Gain Loss On Disposition Of Assets1 0.0000 USD 1 us-gaap/2024
0000885590-25-000020 20240331 Gain Loss Related To Litigation Settlement Gross -6000000.0000 USD 1 0000885590-25-000020
0000885590-25-000020 20240331 Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest -69000000.0000 USD 1 us-gaap/2024
0000885590-25-000020 20250331 Increase Decrease In Accounts Receivable -110000000.0000 USD 1 us-gaap/2024
0000885590-25-000020 20250331 Intangible Assets Net Excluding Goodwill 5297000000.0000 USD 0 us-gaap/2024
0000885590-25-000020 20240331 Investment Income Interest 9000000.0000 USD 1 us-gaap/2024
0000885590-25-000020 20250331 Liabilities 26661000000.0000 USD 0 us-gaap/2024
0000885590-25-000020 20250331 Liabilities And Stockholders Equity 26421000000.0000 USD 0 us-gaap/2024
0000885590-25-000020 20250331 Net Cash Provided By Used In Financing Activities -146000000.0000 USD 1 us-gaap/2024
0000885590-25-000020 20240331 Net Cash Provided By Used In Investing Activities -73000000.0000 USD 1 us-gaap/2024
0000885590-25-000020 20240331 Net Income Loss -64000000.0000 USD 1 us-gaap/2024
0000885590-25-000020 20240331 Noncontrolling Interest Increase From Subsidiary Equity Issuance 0.0000 USD 1 us-gaap/2024
0000885590-25-000020 20250331 Noncontrolling Interest Increase From Subsidiary Equity Issuance 23000000.0000 USD 1 us-gaap/2024 Equity Components= Noncontrolling Interest;
0000885590-25-000020 20240331 Operating Income Loss -244000000.0000 USD 1 us-gaap/2024 Consolidation Items= Corporate Non Segment;
0000885590-25-000020 20240331 Operating Income Loss 812000000.0000 USD 1 us-gaap/2024 Consolidation Items= Operating Segments;
0000885590-25-000020 20250331 Operating Income Loss 816000000.0000 USD 1 us-gaap/2024 Consolidation Items= Operating Segments;
0000885590-25-000020 20250331 Other Assets Noncurrent 380000000.0000 USD 0 us-gaap/2024
0000885590-25-000020 20240331 Payments For Legal Settlements 3000000.0000 USD 1 us-gaap/2024
0000885590-25-000020 20250331 Payments For Proceeds From Hedge Investing Activities -6000000.0000 USD 1 us-gaap/2024
0000885590-25-000020 20240331 Payments To Acquire Intangible Assets 1000000.0000 USD 1 us-gaap/2024
0000885590-25-000020 20250331 Prepaid Expense And Other Assets Current 890000000.0000 USD 0 us-gaap/2024
0000885590-25-000020 20240331 Profit Loss -77000000.0000 USD 1 us-gaap/2024
0000885590-25-000020 20250331 Profit Loss -58000000.0000 USD 1 us-gaap/2024 Equity Components= Retained Earnings;
0000885590-25-000020 20250331 Restricted Cash Current 23000000.0000 USD 0 us-gaap/2024 Fair Value By Measurement Frequency= Fair Value Measurements Recurring;
0000885590-25-000020 20250331 Restructuring Charges And Initial Public Offering Costs 1000000.0000 USD 1 0000885590-25-000020
0000885590-25-000020 20240331 Revenue From Contract With Customer Excluding Assessed Tax 2153000000.0000 USD 1 us-gaap/2024
0000885590-25-000020 20240331 Revenue From Contract With Customer Excluding Assessed Tax 499000000.0000 USD 1 us-gaap/2024 Business Segments= Salix Segment; Consolidation Items= Operating Segments;
0000885590-25-000020 20240331 Revenue From Contract With Customer Excluding Assessed Tax 2153000000.0000 USD 1 us-gaap/2024 Consolidation Items= Operating Segments;
0000885590-25-000020 20240331 Selling General And Administrative Expense 794000000.0000 USD 1 us-gaap/2024
0000885590-25-000020 20231231 Stockholders Equity Including Portion Attributable To Noncontrolling Interest -1881000000.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0000885590-25-000020 20231231 Stockholders Equity Including Portion Attributable To Noncontrolling Interest -1022000000.0000 USD 0 us-gaap/2024 Equity Components= Parent;
0000885590-25-000020 20240331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest -174000000.0000 USD 0 us-gaap/2024
0000885590-25-000020 20240331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 164000000.0000 USD 0 us-gaap/2024 Equity Components= Additional Paid In Capital;
0000885590-25-000020 20250331 Stock Issued During Period Value Share Based Compensation 0.0000 USD 1 us-gaap/2024
0000885590-25-000020 20250331 Weighted Average Number Of Diluted Shares Outstanding 369600000.0000 shares 1 us-gaap/2024
0000885590-25-000020 20250331 Derivative Gain Excluded Component 3000000.0000 USD 1 0000885590-25-000020
0000885590-25-000020 20231231 Goodwill 11183000000.0000 USD 0 us-gaap/2024
0000885590-25-000020 20231231 Goodwill 5314000000.0000 USD 0 us-gaap/2024 Business Segments= Bausch Lomb;
0000885590-25-000020 20250331 Goodwill 11153000000.0000 USD 0 us-gaap/2024
0000885590-25-000020 20250331 Goodwill 5306000000.0000 USD 0 us-gaap/2024 Business Segments= Bausch Lomb;
0000885590-25-000020 20250331 Goodwill 3159000000.0000 USD 0 us-gaap/2024 Business Segments= Salix Segment;
0000885590-25-000020 20241231 Liabilities 26845000000.0000 USD 0 us-gaap/2024
0000885590-25-000020 20241231 Liabilities Current 6752000000.0000 USD 0 us-gaap/2024
0000885590-25-000020 20240331 Net Cash Provided By Used In Financing Activities -340000000.0000 USD 1 us-gaap/2024
0000885590-25-000020 20240331 Net Cash Provided By Used In Operating Activities 211000000.0000 USD 1 us-gaap/2024
0000885590-25-000020 20240331 Noncontrolling Interest Increase From Subsidiary Equity Issuance 12000000.0000 USD 1 us-gaap/2024 Equity Components= Noncontrolling Interest;
0000885590-25-000020 20250331 Noncontrolling Interest Increase From Subsidiary Equity Issuance -23000000.0000 USD 1 us-gaap/2024 Equity Components= Parent;
0000885590-25-000020 20240331 Operating Income Loss 242000000.0000 USD 1 us-gaap/2024 Business Segments= Bausch Lomb; Consolidation Items= Operating Segments;
0000885590-25-000020 20250331 Operating Income Loss 371000000.0000 USD 1 us-gaap/2024 Business Segments= Salix Segment; Consolidation Items= Operating Segments;
0000885590-25-000020 20241231 Other Assets Noncurrent 363000000.0000 USD 0 us-gaap/2024
0000885590-25-000020 20240331 Other Comprehensive Income Loss Net Of Tax -36000000.0000 USD 1 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0000885590-25-000020 20240331 Other Comprehensive Income Loss Net Of Tax 2000000.0000 USD 1 us-gaap/2024 Equity Components= Noncontrolling Interest;
0000885590-25-000020 20250331 Other Comprehensive Income Loss Net Of Tax -9000000.0000 USD 1 us-gaap/2024 Equity Components= Noncontrolling Interest;
0000885590-25-000020 20250331 Other Liabilities Noncurrent 761000000.0000 USD 0 us-gaap/2024
0000885590-25-000020 20250331 Other Operating Income Expense Net -15000000.0000 USD 1 us-gaap/2024
0000885590-25-000020 20240331 Payments For Proceeds From Hedge Investing Activities 6000000.0000 USD 1 us-gaap/2024 Derivative Instrument Risk= Currency Swap;
0000885590-25-000020 20250331 Payments Of Debt Issuance Costs 5000000.0000 USD 1 us-gaap/2024
0000885590-25-000020 20250331 Payments Related To Tax Withholding For Share Based Compensation 16000000.0000 USD 1 us-gaap/2024
0000885590-25-000020 20240331 Payments To Acquire Property Plant And Equipment 82000000.0000 USD 1 us-gaap/2024
0000885590-25-000020 20250331 Proceeds From Issuance Of Long Term Debt 50000000.0000 USD 1 us-gaap/2024
0000885590-25-000020 20240331 Profit Loss -64000000.0000 USD 1 us-gaap/2024 Equity Components= Retained Earnings;
0000885590-25-000020 20250331 Profit Loss -86000000.0000 USD 1 us-gaap/2024
0000885590-25-000020 20240331 Research And Development Expense Excluding Acquired In Process Cost 5000000.0000 USD 1 us-gaap/2024 Business Segments= International Rx; Consolidation Items= Operating Segments;
0000885590-25-000020 20250331 Research And Development Expense Excluding Acquired In Process Cost 28000000.0000 USD 1 us-gaap/2024 Business Segments= Bausch Lomb; Consolidation Items= Operating Segments;
0000885590-25-000020 20250331 Research And Development Expense Excluding Acquired In Process Cost 6000000.0000 USD 1 us-gaap/2024 Business Segments= International Rx; Consolidation Items= Operating Segments;
0000885590-25-000020 20241231 Restricted Cash Current 20000000.0000 USD 0 us-gaap/2024 Fair Value By Measurement Frequency= Fair Value Measurements Recurring;
0000885590-25-000020 20250331 Restricted Cash Current 0.0000 USD 0 us-gaap/2024 Fair Value By Fair Value Hierarchy Level= Fair Value Inputs Level3; Fair Value By Measurement Frequency= Fair Value Measurements Recurring;
0000885590-25-000020 20240331 Revenue From Contract With Customer Excluding Assessed Tax 88000000.0000 USD 1 us-gaap/2024 Business Segments= Solta Medical Segment; Consolidation Items= Operating Segments;
0000885590-25-000020 20250331 Revenue From Contract With Customer Excluding Assessed Tax 2259000000.0000 USD 1 us-gaap/2024
0000885590-25-000020 20250331 Revenue From Contract With Customer Excluding Assessed Tax 1137000000.0000 USD 1 us-gaap/2024 Business Segments= Bausch Lomb; Consolidation Items= Operating Segments;
0000885590-25-000020 20240331 Selling General And Administrative Expense 405000000.0000 USD 1 us-gaap/2024 Business Segments= Bausch Lomb; Consolidation Items= Operating Segments;
0000885590-25-000020 20240331 Selling General And Administrative Expense 48000000.0000 USD 1 us-gaap/2024 Business Segments= Diversified Segment; Consolidation Items= Operating Segments;
0000885590-25-000020 20241231 Stockholders Equity Including Portion Attributable To Noncontrolling Interest -17000000.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Defined Benefit Plans Adjustment;
0000885590-25-000020 20241231 Stockholders Equity Including Portion Attributable To Noncontrolling Interest -2179000000.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0000885590-25-000020 20240331 Stock Issued During Period Shares Share Based Compensation 1500000.0000 shares 1 us-gaap/2024 Equity Components= Common Stock;

Description
Field Name Field Description
adsh Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission.
tag The unique identifier (name) for a tag in a specific taxonomy release.
version For a standard tag, an identifier for the taxonomy; otherwise the accession number where the tag was defined.
ddate The end date for the data value, rounded to the nearest month end.
qtrs The count of the number of quarters represented by the data value, rounded to the nearest whole number. “0” indicates it is a point-in-time value.
uom The unit of measure for the value.
segments Tags used to represent axis and member reporting.
coreg If specified, indicates a specific co-registrant, the parent company, or other entity (e.g., guarantor). NULL indicates the consolidated entity.
value The value. This is not scaled, it is as found in the Interactive Data file, but is limited to four digits to the right of the decimal point.
footnote The text of any superscripted footnotes on the value, as shown on the statement page, truncated to 512 characters, or if there is no footnote, then this field will be blank.

Tags

tag version custom abstract datatype iord crdr tlabel doc
Increase Decrease In Accounts Receivable us-gaap/2024 0 0 monetary D C Increase (Decrease) in Accounts Receivable The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.
Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest us-gaap/2024 0 0 monetary D C Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.
Proceeds From Issuance Of Long Term Debt us-gaap/2024 0 0 monetary D D Proceeds from Issuance of Long-Term Debt The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.
Assets Current us-gaap/2024 0 0 monetary I D Assets, Current Amount of asset recognized for present right to economic benefit, classified as current.
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents us-gaap/2024 0 0 monetary I D Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
Revenue From Contract With Customer Excluding Assessed Tax us-gaap/2024 0 0 monetary D C Revenue from Contract with Customer, Excluding Assessed Tax Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.
Payment For Contingent Consideration Liability Including Accretion Operating Activities 0000885590-25-000020 1 0 monetary D C Payment For Contingent Consideration Liability, Including Accretion, Operating Activities Payment For Contingent Consideration Liability, Including Accretion, Operating Activities
Depreciation And Amortization us-gaap/2024 0 0 monetary D D Depreciation, Depletion and Amortization, Nonproduction The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.
Payments To Acquire Property Plant And Equipment us-gaap/2024 0 0 monetary D C Payments to Acquire Property, Plant, and Equipment The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.
Stockholders Equity Including Portion Attributable To Noncontrolling Interest us-gaap/2024 0 0 monetary I C Equity, Including Portion Attributable to Noncontrolling Interest Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.
Amortization Interim Contract And Inventory Step From Acquisition 0000885590-25-000020 1 0 monetary D D Amortization, Interim Contract And Inventory Step From Acquisition Amortization, Interim Contract And Inventory Step From Acquisition
Comprehensive Income Net Of Tax us-gaap/2024 0 0 monetary D C Comprehensive Income (Loss), Net of Tax, Attributable to Parent Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest us-gaap/2024 0 0 monetary D D Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.
Deferred Income Tax Assets Net us-gaap/2024 0 0 monetary I D Deferred Income Tax Assets, Net Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest us-gaap/2024 0 0 monetary D C Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
Liabilities us-gaap/2024 0 0 monetary I C Liabilities Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.
Liabilities And Stockholders Equity us-gaap/2024 0 0 monetary I C Liabilities and Equity Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
Net Income Loss Attributable To Noncontrolling Interest us-gaap/2024 0 0 monetary D D Net Income (Loss) Attributable to Noncontrolling Interest Amount of Net Income (Loss) attributable to noncontrolling interest.
Retained Earnings Accumulated Deficit us-gaap/2024 0 0 monetary I C Retained Earnings (Accumulated Deficit) Amount of accumulated undistributed earnings (deficit).
Business Combination Contingent Consideration Noncurrent Liability 0000885590-25-000020 1 0 monetary I C Business Combination, Contingent Consideration, Noncurrent Liability Business Combination, Contingent Consideration, Noncurrent Liability
Derivative Gain Excluded Component 0000885590-25-000020 1 0 monetary D C Derivative, Gain, Excluded Component Derivative, Gain, Excluded Component
Accumulated Other Comprehensive Income Loss Net Of Tax us-gaap/2024 0 0 monetary I C Accumulated Other Comprehensive Income (Loss), Net of Tax Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.
Adjustments Related To Tax Withholding For Share Based Compensation us-gaap/2024 0 0 monetary D D Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.
Asset Impairment Charges us-gaap/2024 0 0 monetary D D Asset Impairment Charges Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.
Common Stock Shares Outstanding us-gaap/2024 0 0 shares I Common Stock, Shares, Outstanding Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
Gain Loss On Disposition Of Assets1 us-gaap/2024 0 0 monetary D C Gain (Loss) on Disposition of Assets Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.
Income Tax Expense Benefit us-gaap/2024 0 0 monetary D D Income Tax Expense (Benefit) Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Net Income Loss us-gaap/2024 0 0 monetary D C Net Income (Loss) Attributable to Parent The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Payments For Legal Settlements us-gaap/2024 0 0 monetary D C Payments for Legal Settlements The amount of cash paid for the settlement of litigation or for other legal issues during the period.
Payments Of Debt Issuance Costs us-gaap/2024 0 0 monetary D C Payments of Debt Issuance Costs The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.
Receivables Net Current us-gaap/2024 0 0 monetary I D Receivables, Net, Current The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.
Restricted Cash Current us-gaap/2024 0 0 monetary I D Restricted Cash, Current Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.
Stockholders Equity us-gaap/2024 0 0 monetary I C Equity, Attributable to Parent Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.
Stock Issued During Period Value Share Based Compensation us-gaap/2024 0 0 monetary D C Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).
Weighted Average Number Of Diluted Shares Outstanding us-gaap/2024 0 0 shares D Weighted Average Number of Shares Outstanding, Diluted The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
Assets us-gaap/2024 0 0 monetary I D Assets Amount of asset recognized for present right to economic benefit.
Common Stock Shares Issued us-gaap/2024 0 0 shares I Common Stock, Shares, Issued Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
Cost Of Goods And Services Sold us-gaap/2024 0 0 monetary D D Cost of Goods and Services Sold The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.
Earnings Per Share Diluted us-gaap/2024 0 0 perShare D Earnings Per Share, Diluted The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents us-gaap/2024 0 0 monetary D D Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
Other Assets Noncurrent us-gaap/2024 0 0 monetary I D Other Assets, Noncurrent Amount of noncurrent assets classified as other.
Payments To Acquire Intangible Assets us-gaap/2024 0 0 monetary D C Payments to Acquire Intangible Assets The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.
Liabilities Current us-gaap/2024 0 0 monetary I C Liabilities, Current Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax us-gaap/2024 0 0 monetary D C Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.
Other Operating Income Expense Net us-gaap/2024 0 0 monetary D C Other Operating Income (Expense), Net The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.
Proceeds From Sale And Maturity Of Marketable Securities us-gaap/2024 0 0 monetary D D Proceeds from Sale and Maturity of Marketable Securities The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.
Accrued Liabilities Current us-gaap/2024 0 0 monetary I C Accrued Liabilities, Current Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
Repayments Of Long Term Debt us-gaap/2024 0 0 monetary D C Repayments of Long-Term Debt The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.
Research And Development Expense Excluding Acquired In Process Cost us-gaap/2024 0 0 monetary D D Research and Development Expense (Excluding Acquired in Process Cost) Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.
Selling General And Administrative Expense us-gaap/2024 0 0 monetary D D Selling, General and Administrative Expense The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.
Share Based Compensation us-gaap/2024 0 0 monetary D D Share-Based Payment Arrangement, Noncash Expense Amount of noncash expense for share-based payment arrangement.
Allowances For Losses On Accounts Receivable And Inventories 0000885590-25-000020 1 0 monetary D D Allowances for Losses on Accounts Receivable and Inventories Amount of the current period expense charged against operations (1) for the purpose of reducing receivables to an amount that approximates their net realizable value and (2) the charge to cost of goods sold that represents the reduction of the carrying amount of inventory, generally attributable to obsolescence or market conditions.
Amortization Of Intangible Assets Excluding Amortization Allocated To Revenues Cost Of Good Sold 0000885590-25-000020 1 0 monetary D D Amortization Of Intangible Assets Excluding Amortization Allocated To Revenues Cost Of Good Sold Amount of intangible asset amortization expense excluding amortization allocated to alliance and royalty revenue and cost of goods sold during the period.
Restructuring Charges And Initial Public Offering Costs 0000885590-25-000020 1 0 monetary D D Restructuring Charges And Initial Public Offering Costs Restructuring Charges And Initial Public Offering Costs
Amortization Of Financing Costs And Discounts us-gaap/2024 0 0 monetary D D Amortization of Debt Issuance Costs and Discounts Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.
Cash And Cash Equivalents At Carrying Value us-gaap/2024 0 0 monetary I D Cash and Cash Equivalents, at Carrying Value Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
Foreign Currency Transaction Gain Loss Before Tax us-gaap/2024 0 0 monetary D C Gain (Loss), Foreign Currency Transaction, before Tax Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction.
Increase Decrease In Inventories us-gaap/2024 0 0 monetary D C Increase (Decrease) in Inventories The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.
Increase Decrease In Prepaid Deferred Expense And Other Assets us-gaap/2024 0 0 monetary D C Increase (Decrease) in Prepaid Expense and Other Assets Amount of increase (decrease) in prepaid expenses, and assets classified as other.
Interest Expense Debt us-gaap/2024 0 0 monetary D D Interest Expense, Debt Amount of the cost of borrowed funds accounted for as interest expense for debt.
Other Comprehensive Income Loss Net Of Tax us-gaap/2024 0 0 monetary D C Other Comprehensive Income (Loss), Net of Tax Amount after tax and reclassification adjustments of other comprehensive income (loss).
Profit Loss us-gaap/2024 0 0 monetary D C Net Income (Loss), Including Portion Attributable to Noncontrolling Interest The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.
Deferred Income Tax Noncash Expense Benefit 0000885590-25-000020 1 0 monetary D D Deferred Income Tax Noncash Expense (Benefit) The noncash component of income tax expense for the period representing the increase (decrease) in the entity's deferred tax assets and liabilities pertaining to continuing operations.
Foreign Currency Transaction And Other Gain Loss Before Tax 0000885590-25-000020 1 0 monetary D C Foreign Currency Transaction And Other Gain (Loss), Before Tax Foreign Currency Transaction And Other Gain (Loss), Before Tax
Payments To Acquire Businesses And For Other Investments 0000885590-25-000020 1 0 monetary D C Payments To Acquire Businesses And For Other Investments Payments To Acquire Businesses And For Other Investments
Costs And Expenses us-gaap/2024 0 0 monetary D D Costs and Expenses Total costs of sales and operating expenses for the period.
Goodwill us-gaap/2024 0 0 monetary I D Goodwill Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.
Intangible Assets Net Excluding Goodwill us-gaap/2024 0 0 monetary I D Intangible Assets, Net (Excluding Goodwill) Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.
Net Cash Provided By Used In Operating Activities us-gaap/2024 0 0 monetary D Net Cash Provided by (Used in) Operating Activities Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
Operating Income Loss us-gaap/2024 0 0 monetary D C Operating Income (Loss) The net result for the period of deducting operating expenses from operating revenues.
Other Liabilities Noncurrent us-gaap/2024 0 0 monetary I C Other Liabilities, Noncurrent Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.
Prepaid Expense And Other Assets Current us-gaap/2024 0 0 monetary I D Prepaid Expense and Other Assets, Current Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.
Inventory Net us-gaap/2024 0 0 monetary I D Inventory, Net Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.
Common Stock Value us-gaap/2024 0 0 monetary I C Common Stock, Value, Issued Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
Payments For Proceeds From Hedge Investing Activities us-gaap/2024 0 0 monetary D C Payments for (Proceeds from) Hedge, Investing Activities The cash outflow or inflow for a financial contract that meets the hedge criteria as either a cash flow hedge, fair value hedge, or hedge of a net investment in a foreign operation.
Net Cash Provided By Used In Financing Activities us-gaap/2024 0 0 monetary D D Net Cash Provided by (Used in) Financing Activities Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Gain Loss Related To Litigation Settlement Gross 0000885590-25-000020 1 0 monetary D C Gain (Loss) Related To Litigation Settlement, Gross Gain (Loss) Related to Litigation Settlement, Gross payments not offset by insurance proceeds.
Accounts Payable Current us-gaap/2024 0 0 monetary I C Accounts Payable, Current Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
Additional Paid In Capital Common Stock us-gaap/2024 0 0 monetary I C Additional Paid in Capital, Common Stock Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect us-gaap/2024 0 0 monetary D D Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
Commitments And Contingencies us-gaap/2024 0 0 monetary I C Commitments and Contingencies Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.
Gains Losses On Extinguishment Of Debt us-gaap/2024 0 0 monetary D C Gain (Loss) on Extinguishment of Debt Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.
Deferred Income Tax Liabilities Net us-gaap/2024 0 0 monetary I C Deferred Income Tax Liabilities, Net Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.
Noncontrolling Interest Increase From Subsidiary Equity Issuance us-gaap/2024 0 0 monetary D C Noncontrolling Interest, Increase from Subsidiary Equity Issuance Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders.
Payments Related To Tax Withholding For Share Based Compensation us-gaap/2024 0 0 monetary D C Payment, Tax Withholding, Share-Based Payment Arrangement Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Asset Cash 0000885590-25-000020 1 0 monetary D D Business Combination, Contingent Consideration Arrangements Change in Amount of Contingent Consideration Asset Cash This element represents the cash-flow impact of any change, including any differences arising upon settlement, recognized during the reporting period in the value of an asset or assets, arising from an item of contingent consideration, recognized in a business combination.
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value us-gaap/2024 0 0 monetary D C APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.
Earnings Per Share Basic us-gaap/2024 0 0 perShare D Earnings Per Share, Basic The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
Increase Decrease In Accounts Payable And Accrued Liabilities us-gaap/2024 0 0 monetary D D Increase (Decrease) in Accounts Payable and Accrued Liabilities The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.
Investment Income Interest us-gaap/2024 0 0 monetary D C Investment Income, Interest Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.
Net Cash Provided By Used In Investing Activities us-gaap/2024 0 0 monetary D D Net Cash Provided by (Used in) Investing Activities Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
Payment For Contingent Consideration Liability Financing Activities us-gaap/2024 0 0 monetary D C Payment for Contingent Consideration Liability, Financing Activities Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.
Payments To Acquire Marketable Securities us-gaap/2024 0 0 monetary D C Payments to Acquire Marketable Securities Amount of cash outflow for purchase of marketable security.
Proceeds From Divestiture Of Businesses Net Of Cash Divested us-gaap/2024 0 0 monetary D D Proceeds from Divestiture of Businesses, Net of Cash Divested This element represents the cash inflow during the period from the sale of a component of the entity.
Long Term Debt Current us-gaap/2024 0 0 monetary I C Long-Term Debt, Current Maturities Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation.
Long Term Debt Noncurrent us-gaap/2024 0 0 monetary I C Long-Term Debt, Excluding Current Maturities Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.
Minority Interest us-gaap/2024 0 0 monetary I C Equity, Attributable to Noncontrolling Interest Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity.
Property Plant And Equipment Net us-gaap/2024 0 0 monetary I D Property, Plant and Equipment, Net Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
Stock Issued During Period Shares Share Based Compensation us-gaap/2024 0 0 shares D Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).
Weighted Average Number Of Shares Outstanding Basic us-gaap/2024 0 0 shares D Weighted Average Number of Shares Outstanding, Basic Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.

Description
Field Name Field Description
tag The unique identifier (name) for a tag in a specific taxonomy release.
version For a standard tag, an identifier for the taxonomy; otherwise the accession number where the tag was defined.
custom 1 if tag is custom (version=adsh), 0 if it is standard. Note: This flag is technically redundant with the version and adsh columns.
abstract 1 if the tag is not used to represent a numeric fact.
datatype If abstract=1, then NULL, otherwise the data type (e.g., monetary) for the tag.
iord If abstract=1, then NULL; otherwise, “I” if the value is a point-in time, or “D” if the value is a duration.
crdr If datatype = monetary, then the tag’s natural accounting balance (debit or credit); if not defined, then NULL.
tlabel If a standard tag, then the label text provided by the taxonomy, otherwise the text provided by the filer. A tag which had neither would have a NULL value here.
doc The detailed definition for the tag. If a standard tag, then the text provided by the taxonomy, otherwise the text assigned by the filer. Some tags have neither, and this field is NULL.

Presentation of Statements

adsh report line stmt inpth rfile tag version plabel negating
0000885590-25-000020 2 3 BS 0 H Cash And Cash Equivalents At Carrying Value us-gaap/2024 Cash and cash equivalents 0
0000885590-25-000020 2 4 BS 0 H Restricted Cash Current us-gaap/2024 Restricted cash 0
0000885590-25-000020 2 5 BS 0 H Receivables Net Current us-gaap/2024 Trade receivables, net 0
0000885590-25-000020 2 6 BS 0 H Inventory Net us-gaap/2024 Inventories, net 0
0000885590-25-000020 2 7 BS 0 H Prepaid Expense And Other Assets Current us-gaap/2024 Prepaid expenses and other current assets 0
0000885590-25-000020 2 8 BS 0 H Assets Current us-gaap/2024 Total current assets 0
0000885590-25-000020 2 9 BS 0 H Property Plant And Equipment Net us-gaap/2024 Property, plant and equipment, net 0
0000885590-25-000020 2 10 BS 0 H Intangible Assets Net Excluding Goodwill us-gaap/2024 Intangible assets, net 0
0000885590-25-000020 2 11 BS 0 H Goodwill us-gaap/2024 Goodwill 0
0000885590-25-000020 2 12 BS 0 H Deferred Income Tax Assets Net us-gaap/2024 Deferred tax assets, net 0
0000885590-25-000020 2 13 BS 0 H Other Assets Noncurrent us-gaap/2024 Other non-current assets 0
0000885590-25-000020 2 14 BS 0 H Assets us-gaap/2024 Total assets 0
0000885590-25-000020 2 17 BS 0 H Accounts Payable Current us-gaap/2024 Accounts payable 0
0000885590-25-000020 2 18 BS 0 H Accrued Liabilities Current us-gaap/2024 Accrued and other current liabilities 0
0000885590-25-000020 2 19 BS 0 H Long Term Debt Current us-gaap/2024 Current portion of long-term debt 0
0000885590-25-000020 2 20 BS 0 H Liabilities Current us-gaap/2024 Total current liabilities 0
0000885590-25-000020 2 21 BS 0 H Business Combination Contingent Consideration Noncurrent Liability 0000885590-25-000020 Acquisition-related contingent consideration 0
0000885590-25-000020 2 22 BS 0 H Long Term Debt Noncurrent us-gaap/2024 Non-current portion of long-term debt 0
0000885590-25-000020 2 23 BS 0 H Deferred Income Tax Liabilities Net us-gaap/2024 Deferred tax liabilities, net 0
0000885590-25-000020 2 24 BS 0 H Other Liabilities Noncurrent us-gaap/2024 Other non-current liabilities 0
0000885590-25-000020 2 25 BS 0 H Liabilities us-gaap/2024 Total liabilities 0
0000885590-25-000020 2 26 BS 0 H Commitments And Contingencies us-gaap/2024 Commitments and contingencies (Note 17) 0
0000885590-25-000020 2 28 BS 0 H Common Stock Value us-gaap/2024 Common shares, no par value, unlimited shares authorized, 369,539,455 and 367,843,058 issued and outstanding at March 31, 2025 and December 31, 2024, respectively 0
0000885590-25-000020 2 29 BS 0 H Additional Paid In Capital Common Stock us-gaap/2024 Additional paid-in capital 0
0000885590-25-000020 2 30 BS 0 H Retained Earnings Accumulated Deficit us-gaap/2024 Accumulated deficit 0
0000885590-25-000020 2 31 BS 0 H Accumulated Other Comprehensive Income Loss Net Of Tax us-gaap/2024 Accumulated other comprehensive loss 0
0000885590-25-000020 2 32 BS 0 H Stockholders Equity us-gaap/2024 Total Bausch Health Companies Inc. shareholders deficit 0
0000885590-25-000020 2 33 BS 0 H Minority Interest us-gaap/2024 Noncontrolling interest 0
0000885590-25-000020 2 34 BS 0 H Stockholders Equity Including Portion Attributable To Noncontrolling Interest us-gaap/2024 Total deficit 0
0000885590-25-000020 2 35 BS 0 H Liabilities And Stockholders Equity us-gaap/2024 Total liabilities and deficit 0
0000885590-25-000020 3 1 BS 1 H Common Stock Shares Issued us-gaap/2024 Common shares, issued (in shares) 0
0000885590-25-000020 3 2 BS 1 H Common Stock Shares Outstanding us-gaap/2024 Common shares, outstanding (in shares) 0
0000885590-25-000020 4 8 IS 0 H Revenue From Contract With Customer Excluding Assessed Tax us-gaap/2024 Revenues 0
0000885590-25-000020 4 10 IS 0 H Cost Of Goods And Services Sold us-gaap/2024 Cost of goods sold (excluding amortization and impairments of intangible assets) and Cost of other revenues 0
0000885590-25-000020 4 11 IS 0 H Selling General And Administrative Expense us-gaap/2024 Selling, general and administrative 0
0000885590-25-000020 4 12 IS 0 H Research And Development Expense Excluding Acquired In Process Cost us-gaap/2024 Research and development 0
0000885590-25-000020 4 13 IS 0 H Amortization Of Intangible Assets Excluding Amortization Allocated To Revenues Cost Of Good Sold 0000885590-25-000020 Amortization of intangible assets 0
0000885590-25-000020 4 14 IS 0 H Asset Impairment Charges us-gaap/2024 Asset impairments 0
0000885590-25-000020 4 15 IS 0 H Restructuring Charges And Initial Public Offering Costs 0000885590-25-000020 Restructuring, integration and separation costs 0
0000885590-25-000020 4 16 IS 0 H Other Operating Income Expense Net us-gaap/2024 Other expense, net 1
0000885590-25-000020 4 17 IS 0 H Costs And Expenses us-gaap/2024 Total expenses 0
0000885590-25-000020 4 18 IS 0 H Operating Income Loss us-gaap/2024 Operating income 0
0000885590-25-000020 4 19 IS 0 H Investment Income Interest us-gaap/2024 Interest income 0
0000885590-25-000020 4 20 IS 0 H Interest Expense Debt us-gaap/2024 Interest expense 1
0000885590-25-000020 4 21 IS 0 H Gains Losses On Extinguishment Of Debt us-gaap/2024 Gain on extinguishment of debt 0
0000885590-25-000020 4 22 IS 0 H Foreign Currency Transaction Gain Loss Before Tax us-gaap/2024 Foreign exchange and other 0
0000885590-25-000020 4 23 IS 0 H Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest us-gaap/2024 Loss before income taxes 0
0000885590-25-000020 4 24 IS 0 H Income Tax Expense Benefit us-gaap/2024 Provision for income taxes 1
0000885590-25-000020 4 25 IS 0 H Profit Loss us-gaap/2024 Net loss 0
0000885590-25-000020 4 26 IS 0 H Net Income Loss Attributable To Noncontrolling Interest us-gaap/2024 Net loss attributable to noncontrolling interest 1
0000885590-25-000020 4 27 IS 0 H Net Income Loss us-gaap/2024 Net loss attributable to Bausch Health Companies Inc. 0
0000885590-25-000020 4 28 IS 0 H Earnings Per Share Basic us-gaap/2024 Basic loss per share attributable to Bausch Health Companies Inc. (in dollars per share) 0
0000885590-25-000020 4 29 IS 0 H Earnings Per Share Diluted us-gaap/2024 Diluted loss per share attributable to Bausch Health Companies Inc. (in dollars per share) 0
0000885590-25-000020 4 30 IS 0 H Weighted Average Number Of Shares Outstanding Basic us-gaap/2024 Basic weighted-average common shares (in shares) 0
0000885590-25-000020 4 31 IS 0 H Weighted Average Number Of Diluted Shares Outstanding us-gaap/2024 Diluted weighted-average common shares (in shares) 0
0000885590-25-000020 5 1 CI 0 H Profit Loss us-gaap/2024 Net loss 0
0000885590-25-000020 5 3 CI 0 H Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax us-gaap/2024 Foreign currency translation adjustment 0
0000885590-25-000020 5 4 CI 0 H Other Comprehensive Income Loss Net Of Tax us-gaap/2024 Other comprehensive income (loss) 0
0000885590-25-000020 5 5 CI 0 H Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest us-gaap/2024 Comprehensive income (loss) 0
0000885590-25-000020 5 6 CI 0 H Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest us-gaap/2024 Comprehensive loss attributable to noncontrolling interest 1
0000885590-25-000020 5 7 CI 0 H Comprehensive Income Net Of Tax us-gaap/2024 Comprehensive income (loss) attributable to Bausch Health Companies Inc. 0
0000885590-25-000020 6 12 EQ 0 H Common Stock Shares Issued us-gaap/2024 Beginning Balance (in shares) 0
0000885590-25-000020 6 13 EQ 0 H Stockholders Equity Including Portion Attributable To Noncontrolling Interest us-gaap/2024 Beginning Balance 0
0000885590-25-000020 6 14 EQ 0 H Stock Issued During Period Shares Share Based Compensation us-gaap/2024 Common shares issued under share-based compensation plans (in shares) 0
0000885590-25-000020 6 15 EQ 0 H Stock Issued During Period Value Share Based Compensation us-gaap/2024 Common shares issued under share-based compensation plans 0
0000885590-25-000020 6 16 EQ 0 H Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value us-gaap/2024 Share-based compensation 0
0000885590-25-000020 6 17 EQ 0 H Adjustments Related To Tax Withholding For Share Based Compensation us-gaap/2024 Employee withholding taxes related to share-based awards 1
0000885590-25-000020 6 18 EQ 0 H Noncontrolling Interest Increase From Subsidiary Equity Issuance us-gaap/2024 Vesting of B+L equity compensation 0
0000885590-25-000020 6 19 EQ 0 H Profit Loss us-gaap/2024 Net loss 0
0000885590-25-000020 6 20 EQ 0 H Other Comprehensive Income Loss Net Of Tax us-gaap/2024 Other comprehensive income (loss) 0
0000885590-25-000020 6 21 EQ 0 H Common Stock Shares Issued us-gaap/2024 Ending Balance (in shares) 0
0000885590-25-000020 6 22 EQ 0 H Stockholders Equity Including Portion Attributable To Noncontrolling Interest us-gaap/2024 Ending Balance 0
0000885590-25-000020 7 2 CF 0 H Profit Loss us-gaap/2024 Net loss 0
0000885590-25-000020 7 4 CF 0 H Depreciation And Amortization us-gaap/2024 Depreciation and amortization of intangible assets 0
0000885590-25-000020 7 5 CF 0 H Amortization Of Financing Costs And Discounts us-gaap/2024 Amortization and write-off of debt premiums, discounts and issuance costs 0
0000885590-25-000020 7 6 CF 0 H Asset Impairment Charges us-gaap/2024 Asset impairments 0
0000885590-25-000020 7 7 CF 0 H Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Asset Cash 0000885590-25-000020 Acquisition-related contingent consideration 0
0000885590-25-000020 7 8 CF 0 H Allowances For Losses On Accounts Receivable And Inventories 0000885590-25-000020 Allowances for losses on trade receivable and inventories 0
0000885590-25-000020 7 9 CF 0 H Deferred Income Tax Noncash Expense Benefit 0000885590-25-000020 Deferred income taxes 0
0000885590-25-000020 7 10 CF 0 H Gain Loss On Disposition Of Assets1 us-gaap/2024 Net gain on sale of assets 1
0000885590-25-000020 7 11 CF 0 H Gain Loss Related To Litigation Settlement Gross 0000885590-25-000020 Adjustments to accrued legal settlements 1
0000885590-25-000020 7 12 CF 0 H Payments For Legal Settlements us-gaap/2024 Payments of accrued legal settlements 1
0000885590-25-000020 7 13 CF 0 H Share Based Compensation us-gaap/2024 Share-based compensation 0
0000885590-25-000020 7 14 CF 0 H Derivative Gain Excluded Component 0000885590-25-000020 Gain excluded from hedge effectiveness 1
0000885590-25-000020 7 15 CF 0 H Gains Losses On Extinguishment Of Debt us-gaap/2024 Gain on extinguishment of debt 1
0000885590-25-000020 7 16 CF 0 H Payment For Contingent Consideration Liability Including Accretion Operating Activities 0000885590-25-000020 Payments of contingent consideration adjustments, including accretion 1
0000885590-25-000020 7 17 CF 0 H Amortization Interim Contract And Inventory Step From Acquisition 0000885590-25-000020 Amortization of interim contract and inventory step-up resulting from acquisitions 0
0000885590-25-000020 7 18 CF 0 H Foreign Currency Transaction And Other Gain Loss Before Tax 0000885590-25-000020 Foreign exchange and other 1
0000885590-25-000020 7 20 CF 0 H Increase Decrease In Accounts Receivable us-gaap/2024 Trade receivables 1
0000885590-25-000020 7 21 CF 0 H Increase Decrease In Inventories us-gaap/2024 Inventories 1
0000885590-25-000020 7 22 CF 0 H Increase Decrease In Prepaid Deferred Expense And Other Assets us-gaap/2024 Prepaid expenses and other current assets 1
0000885590-25-000020 7 23 CF 0 H Increase Decrease In Accounts Payable And Accrued Liabilities us-gaap/2024 Accounts payable, accrued and other liabilities 0
0000885590-25-000020 7 24 CF 0 H Net Cash Provided By Used In Operating Activities us-gaap/2024 Net cash provided by operating activities 0
0000885590-25-000020 7 26 CF 0 H Payments To Acquire Businesses And For Other Investments 0000885590-25-000020 Acquisitions and other investments 1
0000885590-25-000020 7 27 CF 0 H Payments To Acquire Property Plant And Equipment us-gaap/2024 Purchases of property, plant and equipment 1
0000885590-25-000020 7 28 CF 0 H Payments To Acquire Intangible Assets us-gaap/2024 Acquisition of intangible assets and other assets 1
0000885590-25-000020 7 29 CF 0 H Payments To Acquire Marketable Securities us-gaap/2024 Purchases of marketable securities 1
0000885590-25-000020 7 30 CF 0 H Proceeds From Sale And Maturity Of Marketable Securities us-gaap/2024 Proceeds from sale of marketable securities 0
0000885590-25-000020 7 31 CF 0 H Proceeds From Divestiture Of Businesses Net Of Cash Divested us-gaap/2024 Proceeds from sale of assets and businesses, net of costs to sell 0
0000885590-25-000020 7 32 CF 0 H Payments For Proceeds From Hedge Investing Activities us-gaap/2024 Interest settlements from cross-currency swaps 1
0000885590-25-000020 7 33 CF 0 H Net Cash Provided By Used In Investing Activities us-gaap/2024 Net cash used in investing activities 0
0000885590-25-000020 7 35 CF 0 H Proceeds From Issuance Of Long Term Debt us-gaap/2024 Issuance of long-term debt, net of discounts 0
0000885590-25-000020 7 36 CF 0 H Repayments Of Long Term Debt us-gaap/2024 Repayments of long-term debt 1
0000885590-25-000020 7 37 CF 0 H Payments Related To Tax Withholding For Share Based Compensation us-gaap/2024 Payments of employee withholding taxes related to share-based awards 1
0000885590-25-000020 7 38 CF 0 H Payment For Contingent Consideration Liability Financing Activities us-gaap/2024 Payments of acquisition-related contingent consideration 1
0000885590-25-000020 7 39 CF 0 H Payments Of Debt Issuance Costs us-gaap/2024 Payments of financing costs 1
0000885590-25-000020 7 40 CF 0 H Net Cash Provided By Used In Financing Activities us-gaap/2024 Net cash used in financing activities 0
0000885590-25-000020 7 41 CF 0 H Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents us-gaap/2024 Effect of exchange rate changes on cash, cash equivalents and restricted cash 0
0000885590-25-000020 7 42 CF 0 H Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect us-gaap/2024 Net decrease in cash, cash equivalents and restricted cash 0
0000885590-25-000020 7 43 CF 0 H Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents us-gaap/2024 Cash, cash equivalents and restricted cash, beginning of period 0
0000885590-25-000020 7 44 CF 0 H Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents us-gaap/2024 Cash, cash equivalents and restricted cash, end of period 0
0000885590-25-000020 7 45 CF 0 H Cash And Cash Equivalents At Carrying Value us-gaap/2024 Cash and cash equivalents 0
0000885590-25-000020 7 46 CF 0 H Restricted Cash Current us-gaap/2024 Restricted cash 0
0000885590-25-000020 7 47 CF 0 H Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents us-gaap/2024 Cash, cash equivalents and restricted cash, end of period 0

Description
Field Name Field Description
adsh Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission.
report Represents the report grouping. This field corresponds to the statement (stmt) field, which indicates the type of statement. The numeric value refers to the “R file” as posted on the EDGAR Web site.
line Represents the tag’s presentation line order for a given report. Together with the statement and report field, presentation location, order and grouping can be derived.
stmt The financial statement location to which the value of the “report” field pertains.
inpth Value was presented “parenthetically” instead of in columns within the financial statements. For example: Receivables (net of allowance for bad debts of $200 in 2012) $700.
rfile The type of interactive data file rendered on the EDGAR web site, H = .htm file, X = .xml file.
tag The tag chosen by the filer for this line item.
version The taxonomy identifier if the tag is a standard tag, otherwise adsh.
plabel The text presented on the line item, also known as a “preferred” label.
negating Flag to indicate whether the plabel is negating.